<?xml version="1.0" encoding="UTF-8"?>
<p>Ritonavir (2) and lopinavir (1) were developed to target HIV-1 protease and postulated to inhibit the 3-chymotrypsin-like protease of SARS and MERS, being associated with improved clinical outcomes.
 <xref rid="B232" ref-type="bibr">
  <sup>232</sup>
 </xref> The combination has beneficial effects in marmoset monkeys infected with the MERS-CoV virus.
 <xref rid="B233" ref-type="bibr">
  <sup>233</sup>
 </xref> (1)/(2) may have clinical efficacy against SARS-CoV-2, as seen in the response against SARS-CoV.
 <xref rid="B234" ref-type="bibr">
  <sup>234</sup>
 </xref>
 <italic>In vitro</italic> sensitivity and satisfactory response in a preliminary non-randomised clinical trial of SARS-CoV to (1)/(2) have already been reported, encouraging its testing in SARS-CoV-2.
 <xref rid="B235" ref-type="bibr">
  <sup>235</sup>
 </xref> A total of 199 patients confirmed severe SARS-CoV-2 infection were randomly designated to be given either (1)/(2) (400 mg/100 mg) twice a day for 14 consecutive days plus standard care or standard care alone.
 <xref rid="B220" ref-type="bibr">
  <sup>220</sup>
 </xref> This first trial was not promising, no benefit was observed on clinical improvement, mortality and viral loads on severe COVID-19 patients. Other clinical trials are being carried out and should decide whether these drugs are useful for COVID-19 treatment or not.
</p>
